Now Accepting Proposals:
| Grant | |
Deadline | Amount |
|
|||
| Validation of Novel Combinations and Novel Compounds |
 |
Jun 30 | $200,000 |
The MMRF supports innovative research efforts in the most promising areas of multiple myeloma research through several grant-making programs. The MMRF accepts applications from U.S.-based and international non-profit institutions and universities. Program guidelines and applications are available approximately 6-8 weeks prior to the submission deadline.
MMRF Research Grant Awards
Significant advances in our understanding of the pathophysiology and molecular biology involved in multiple myeloma have identified numerous putative molecular targets for therapeutic intervention. The MMRF welcomes proposals on any and all multiple myeloma related topics to the traditional Research Grant Award Programs.
Special Request for Proposals (RFPs)
MMRF Research Grant Awards
Significant advances in our understanding of the pathophysiology and molecular biology involved in multiple myeloma have identified numerous putative molecular targets for therapeutic intervention. The MMRF welcomes proposals on any and all multiple myeloma related topics to the traditional Research Grant Award Programs.
-
Research Fellows Awards provide funding to researchers with less than five years experience (post graduate degree) and working under the supervision of a research sponsor. Proposals may request up to $75,000 for one year. The deadline to submit an application for the Fellows Award is March 1, 2008. Anticipated applicant notification date is early May.
The RFPs are designed to support research projects outside the scope of the MMRF's traditional Research Grants Program. These special funding opportunities are created to address critical research needs and to advance important research and drug discovery efforts. Programs are subject to funding availability and may change throughout the year.
-
Validation of Novel Combinations and Novel Compounds With a multitude of therapeutic options under investigation for multiple myeloma, the ability to identify those that show the most potential in treating the disease is of critical importance. One of the most effective and efficient ways to do this is through is pre-clinical validation. These awards were developed to advance the science of pre-clinical validation in multiple myeloma.
-
Novel combination therapies and the sequencing of these therapies hold tremendous promise in treating multiple myeloma. The Validation of Novel Combinations proposals should support the testing of several targeted therapeutic agents — either novel or currently available compounds — in innovative, rationally–designed combinations and sequences. Proposals may request up to $200,000 over the course of two years. The deadline to submit an application is June 30, 2008 and applicants will be notified in September.
-
LEAD Awards: LEAD (Leveraging Existing myeloma targets to Accelerate Drug discovery and development), the latest example of several field-innovating programs launched by the MMRF, will bring together and foster collaboration between academic myeloma experts with experts in the biotechnology industry to accelerate drug discovery and development for new treatments for myeloma. The marriage of these two fields of experts will bring new therapeutic entities to be rapidly tested in pre-clinical studies in myeloma. The MMRF has pledged up to $6 million to support multiple projects in this multi-year initiative. The MMRF will accept applications for the LEAD program between June and August 2008. Anticipated applicant notification date is early October.